## Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form 4

VALEANT PH Form 4 September 30, 2		ICALS IN	ITERNA	TION	AL							
FORM 4	4 UNITED	STATES						IGE C	COMMISSION		PPROVAL 3235-0287	
8 9 9								•				
(Print or Type Resp	oonses)											
KOPPES RICHARD Symbol VAI			2. Issuer Name <b>and</b> Ticker or Trading Symbol VALEANT PHARMACEUTICALS INTERNATIONAL [VRX]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	· · · · ·	Middle)	3. Date of (Month/Da 09/28/20	ay/Year]		insaction			X Director Officer (give below)		Owner er (specify	
Filed(Month/Day/Year) Appli _X_F ALISO VIEIO CA 92656 — F					Applicable Line) _X_ Form filed by C	lual or Joint/Group Filing(Check Line) filed by One Reporting Person filed by More than One Reporting						
(City)	(State)	(Zip)	Table	e I - Nor	n-De	erivative S	ecurit	ies Acq	uired, Disposed of	, or Beneficial	ly Owned	
	Transaction Date Aonth/Day/Year)	Execution any		Code	8)	n(A) or Dis (D)	sposed	of	Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial	
Common 09 Stock 09	9/28/2010			D		54,523	D	<u>(1)</u>	0	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	onDerivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amour or Numbe of Shar
Nonqualified Stock Option (right to buy)	\$ 10.05	09/28/2010		D		15,000	(2)	08/01/2010	Common Stock	15,00

## Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form 4

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
1	Director	10% Owner	Officer	Other			
KOPPES RICHARD ONE ENTERPRISE ALISO VIEJO, CA 92656	Х						
Signatures							
Michelle May For Richard H. Koppes		09/28/20	10				
**Signature of Reporting Person		Date					

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

51,266 restricted stock units disposed pursuant to merger agreement between issuer and Biovail Corporation, among others, in exchange for 143,424 Valeant Pharmaceuticals International, Inc. (formerly known as Biovail Corporation) restricted stock units, on the same terms

- and conditions. Remaining 3,257 restricted stock units disposed pursuant to merger agreement between issuer and, among others, Biovail Corporation in exchange for 6,389 shares of Valeant Pharmaceuticals International Inc. common stock. The fair market value of Valeant Pharmaceuticals International, Inc. on the effective date of the merger was \$26.00 per share.
- (2) This option was assumed by Valeant Pharmaceuticals International, Inc. in the merger and replaced with an option to purchase 41,966 shares of Valeant Pharmaceuticals International, Inc. common stock for \$3.59 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.